Transcatheter Pulmonary Valve (TPV) Therapy Market To Reach $66.4 Billion By 2026 | Top Vendors: Medtronic, Edward Lifesciences, Cryolife Inc, and Venus Medtech

According to the current analysis of Reports and Data, the global transcatheter pulmonary valve therapy market was valued at USD 37.8 million in 2018 and is expected to reach USD 66.4 million by the year 2026, at a CAGR of 7.2 percent. Transcatheter Pulmonary Valve Therapy has come up as the treatment of choice in most congenital heart disease patients with degeneration of a previous right ventricular outflow tract repair. To avoid the need for repeat median sternotomy procedures, less invasive catheter-based interventions to treat pulmonary valve dysfunction have been developed over time.

Request for PDF Sample at: https://www.reportsanddata.com/sample-enquiry-form/1067

The global market is driven by the rising incidence of congenital heart diseases and increasing awareness associated with TPV Therapy. For instance, in the United States, the incidence of congenital heart defects ranges between 4 to10 cases per 1,000, clustering around 8 cases per 1,000 live births. Continental variations in birth prevalence have been observed, from about 6.9 cases per 1000 births in Europe to 9.3 cases per 1000 births in Asia. However, the relationship between valve size and balloon waist may reflect selection and procedural bias, which is likely to hinder the market growth

Read more at: https://www.reportsanddata.com/report-detail/transcatheter-pulmonary-valves-tpv-therapy-market

Further key findings from the report suggest
Transcatheter Pulmonary Valve Therapy market is rising at a high growth rate of 7.2 percent in Asia Pacific followed by North America and Europe. High incidence of cardiovascular diseases will drive the demand for the market during forecast period across all regions.

The valuation for balloon expanded transcatheter Valve market was USD 30.5 million in 2017 and is expected to grow to USD 53.0 million by 2026. Benefits associated with transcatheter pulmonary Valve is the key factor supporting the increasing adoption of the theraphy and consequently contributing to the market growth.

Asia Pacific is expected to witness a CAGR of 12.9 percent in the forecast period. Emerging markets such China and Japan are likely to witness high growth
Regional reimbursement scenario is another key regulatory factor for adoption and growth of transcatheter pulmonary valve therapy in the region..
Key participants include Medtronic, Edward Lifesciences, Cryolife Inc, and Venus Medtech.

For the purpose of this report, Reports and Data has segmented the global transcatheter pulmonary valve therapy market on the basis of product, piling method and region:

Type (Revenue, USD Million; 2016–2026)
Balloon expanded
Self-expanded Transcatheter Valve

Application Outlook (Revenue, USD Million; 2016–2026)
Hospitals
Cardiology Centers
Others

Regional Outlook (Revenue, USD Million; 2016–2026)
North America
U.S.
Canada

Europe
Germany
France
U.K.
The Netherlands
Spain
Italy
Rest of Europe

Asia Pacific
China
India
Japan
Rest of Asia-Pacific

Middle East and Africa

Latin America
Brazil

Make an enqurie at: https://www.reportsanddata.com/make-enquiry-form/1067

We are a boutique market intelligence and strategic consulting firm dedicated to make an meaningful impact on businesses across the globe. Our stellar estimation and forecasting models have earned recognition across majority of the business forum across the globe. Our services are arrayed over diverse sectors and industries looking to expand in alternative regions and products.

40 Wall St. 28th floor New York City, NY 10005 United States

This release was published on openPR.